We also offer a comparative assessment of other BTK inhibitors investigated for ITP and discuss rilzabrutinib's potential positioning relative to existing therapies, including thrombopoietin receptor agonists (TPO‐RAs), rituximab, fostamatinib, and immunosuppressants. This evidence concerns the gene BTK and autoimmune thrombocytopenic purpura.